VB_2因具有超高理论比容量(4060 m Ah/g)而成为具有发展潜力的空气电池负极材料。实验以VB_2为负极活性物质,Ni为导电剂,NH_4HCO_3为造孔剂,采用粉末冶金方法制备了大容量VB_2-空气电池用多孔负极片,并探讨了负极片孔隙度对负极所组装...VB_2因具有超高理论比容量(4060 m Ah/g)而成为具有发展潜力的空气电池负极材料。实验以VB_2为负极活性物质,Ni为导电剂,NH_4HCO_3为造孔剂,采用粉末冶金方法制备了大容量VB_2-空气电池用多孔负极片,并探讨了负极片孔隙度对负极所组装空气电池放电性能的影响规律。结果表明,所制备的多孔VB_2负极片放电性能优异,放电比容量可以达到3216~3463 m Ah/g范围内;多孔VB_2负极片放电容量、比容量、库伦效率和比能量均与孔隙度密切相关。当添加15wt%NH_4HCO_3造孔剂时,烧结制备的多孔VB_2负极片的孔隙度为60.91%,此时VB_2-空气电池放电性能最优:放电容量为7792 m Ah,放电比容量为3463 m Ah/g,库伦效率为85.30%,放电比能量为2370 mWh/g。展开更多
Objective： The relationship between apparent diffusion coefficient （ADC） and chemotherapy has been established. However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatoce...Objective： The relationship between apparent diffusion coefficient （ADC） and chemotherapy has been established. However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatocellular carcinoma （HCC） has not been demonstrated. This study was to investigate the ADC changes of ad- vanced HCC under sorafenib treatment. Methods： Athymic mice with HepG2 xenografts were allocated to two groups： control and sorafenib （40 mg/kg, bid）. T2 and diffusion images were acquired at each time point （0, 10, 14, and 18 d post-therapy）. Tumor volume and changes in ADC were calculated. Results： Tumor volumes on Days 10, 14, and 18 after treatment showed significant decreases in the sorafenib-treated group compared with the control. Pretreatment ADC values were not significantly different between the control and treated groups. A slow increase in ADC in the peripheral zone of tumors appeared in the treated group, which was significantly higher compared with the control group on Days 10, 14, and 18. In the central part of tumors on Day 10 after treatment, an increase in ADC appeared in the treated and control groups, the ADC of the control group being significantly lower compared with the treated tumors From Day 10 to Day 14, the ADC map showed a progressive decrease in the central region of tumors in the treated and control groups. However, this change is more significant in the treated groups. Conclusions： Early changes in mean ADC correlated with sorafenib treatment in HCC, which are promising indicators for predicting sorafenib response in this carcinoma.展开更多
基金supported by the National Natural Science Foundation of China(U1832202,11888101,11920101005,12141402,and 12274459)the Chinese Academy of Sciences(QYZDB-SSW-SLH043,XDB33020100,and XDB28000000)+4 种基金the Beijing Municipal Science and Technology Commission(Z171100002017018,and Z200005)the National Key R&D Program of China(2018YFE0202600,2022YFA1403100,and 2022YFA1403800)the Fundamental Research Funds for the Central Universities and Research Funds of Renmin University of China(RUC)(18XNLG14,19XNLG13,19XNLG17,and 20XNH062)the Synergic Extreme Condition User Facility,Beijing,ChinaBeijing National Laboratory for Condensed Matter Physics。
文摘VB_2因具有超高理论比容量(4060 m Ah/g)而成为具有发展潜力的空气电池负极材料。实验以VB_2为负极活性物质,Ni为导电剂,NH_4HCO_3为造孔剂,采用粉末冶金方法制备了大容量VB_2-空气电池用多孔负极片,并探讨了负极片孔隙度对负极所组装空气电池放电性能的影响规律。结果表明,所制备的多孔VB_2负极片放电性能优异,放电比容量可以达到3216~3463 m Ah/g范围内;多孔VB_2负极片放电容量、比容量、库伦效率和比能量均与孔隙度密切相关。当添加15wt%NH_4HCO_3造孔剂时,烧结制备的多孔VB_2负极片的孔隙度为60.91%,此时VB_2-空气电池放电性能最优:放电容量为7792 m Ah,放电比容量为3463 m Ah/g,库伦效率为85.30%,放电比能量为2370 mWh/g。
基金supported by the National Natural Science Foundation of China(No.81071960)the New Teacher Foundation of the Ministry of Education,China(No.20100101120129)the Zhejiang Provincial Medical Science Research Foundation(No.2010KYA064),China
文摘Objective： The relationship between apparent diffusion coefficient （ADC） and chemotherapy has been established. However, whether ADC could be considered as a measure for monitoring response to sorafenib in hepatocellular carcinoma （HCC） has not been demonstrated. This study was to investigate the ADC changes of ad- vanced HCC under sorafenib treatment. Methods： Athymic mice with HepG2 xenografts were allocated to two groups： control and sorafenib （40 mg/kg, bid）. T2 and diffusion images were acquired at each time point （0, 10, 14, and 18 d post-therapy）. Tumor volume and changes in ADC were calculated. Results： Tumor volumes on Days 10, 14, and 18 after treatment showed significant decreases in the sorafenib-treated group compared with the control. Pretreatment ADC values were not significantly different between the control and treated groups. A slow increase in ADC in the peripheral zone of tumors appeared in the treated group, which was significantly higher compared with the control group on Days 10, 14, and 18. In the central part of tumors on Day 10 after treatment, an increase in ADC appeared in the treated and control groups, the ADC of the control group being significantly lower compared with the treated tumors From Day 10 to Day 14, the ADC map showed a progressive decrease in the central region of tumors in the treated and control groups. However, this change is more significant in the treated groups. Conclusions： Early changes in mean ADC correlated with sorafenib treatment in HCC, which are promising indicators for predicting sorafenib response in this carcinoma.
